20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Erasca Inc (ERAS) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 103 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, ERAS reported $0M in revenue and ($125M) in net income.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($3M) | ($4M) | ($4M) | ($3M) | ($1M) | ($1M) | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($153M) | ($131M) | ($180M) | ($142M) | ($247M) | ($125M) | ($109M) | ($13M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($287M) | ($125M) | ($162M) | ($125M) | ($243M) | ($123M) | ($102M) | ($12M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($284M) | ($121M) | ($153M) | ($121M) | ($240M) | ($122M) | ($37M) | ($13M) |
| Earnings Per Share (EPS) | $-0.95 | $-0.44 | $-0.69 | $-1.04 | $-2.49 | $-1.29 | $-5.47 | $-0.13 |
| Shares Outstanding (M) | 311M | 284M | 234M | 120M | 98M | — | — | 95M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $4M | $0M |
| Gross Profit | — | ($1M) | ($1M) | — | ($1M) | ($1M) | ($1M) | ($1M) |
| Gross Margin % | — | — | — | — | — | — | -19.8% | — |
| Operating Income (EBIT) | ($48M) | ($38M) | ($33M) | ($35M) | ($38M) | ($36M) | ($36M) | ($37M) |
| Operating Margin % | — | — | — | — | — | — | -851.1% | — |
| Net Income | ($44M) | ($183M) | ($29M) | ($31M) | ($34M) | ($31M) | ($32M) | ($31M) |
| Net Margin % | — | — | — | — | — | — | -768.2% | — |
| EBITDA | ($43M) | ($183M) | ($28M) | ($30M) | ($30M) | ($30M) | ($31M) | ($30M) |
| Earnings Per Share (EPS) | $-0.14 | $-0.60 | $-0.10 | $-0.11 | $-0.12 | $-0.11 | $-0.14 | $-0.14 |
| Shares Outstanding (M) | 311M | 304M | 284M | 284M | 283M | 283M | 234M | 226M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($98M) | ($95M) | ($109M) | ($101M) | ($103M) | ($80M) | ($33M) | ($10M) |
| Capital Expenditures (CapEx) | $0M | $0M | $23M | $2M | $17M | $19M | $39M | $1M |
| Free Cash Flow (FCF) | ($98M) | ($96M) | ($132M) | ($103M) | ($120M) | ($98M) | ($71M) | ($11M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($27M) | ($27M) | ($22M) | ($22M) | ($21M) | ($32M) | ($25M) | ($22M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($27M) | ($27M) | ($22M) | ($22M) | ($21M) | ($32M) | ($25M) | ($22M) |
| FCF Margin % | — | — | — | — | — | — | -585.4% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $435M | $396M | $503M | $395M | $515M | $501M | $125M | $56M |
| Cash & Cash Equivalents | $43M | $74M | $68M | $93M | $284M | $360M | $65M | $30M |
| Total Liabilities | $73M | $71M | $79M | $79M | $103M | $45M | $239M | $69M |
| Total Debt (Short + Long-Term) | $5M | $5M | $9M | $4M | $3M | $1M | $1M | $1M |
| Total Shareholders' Equity | $362M | $325M | $423M | $317M | $412M | $457M | ($114M) | ($14M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ERAS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms